JP2019526573A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526573A5
JP2019526573A5 JP2019511860A JP2019511860A JP2019526573A5 JP 2019526573 A5 JP2019526573 A5 JP 2019526573A5 JP 2019511860 A JP2019511860 A JP 2019511860A JP 2019511860 A JP2019511860 A JP 2019511860A JP 2019526573 A5 JP2019526573 A5 JP 2019526573A5
Authority
JP
Japan
Prior art keywords
polysaccharide
carrier protein
vaccine
conjugate
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511860A
Other languages
English (en)
Japanese (ja)
Other versions
JP6764021B2 (ja
JP2019526573A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049856 external-priority patent/WO2018045286A1/en
Publication of JP2019526573A publication Critical patent/JP2019526573A/ja
Publication of JP2019526573A5 publication Critical patent/JP2019526573A5/ja
Application granted granted Critical
Publication of JP6764021B2 publication Critical patent/JP6764021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511860A 2016-09-02 2017-09-01 ナイセリア・メニンギティディスのワクチン Active JP6764021B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662383279P 2016-09-02 2016-09-02
US62/383,279 2016-09-02
US201762468695P 2017-03-08 2017-03-08
US62/468,695 2017-03-08
US201762505525P 2017-05-12 2017-05-12
US62/505,525 2017-05-12
PCT/US2017/049856 WO2018045286A1 (en) 2016-09-02 2017-09-01 Neisseria meningitidis vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020150938A Division JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン

Publications (3)

Publication Number Publication Date
JP2019526573A JP2019526573A (ja) 2019-09-19
JP2019526573A5 true JP2019526573A5 (enExample) 2020-05-14
JP6764021B2 JP6764021B2 (ja) 2020-09-30

Family

ID=59846741

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019511860A Active JP6764021B2 (ja) 2016-09-02 2017-09-01 ナイセリア・メニンギティディスのワクチン
JP2020150938A Active JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン
JP2022021720A Active JP7329087B2 (ja) 2016-09-02 2022-02-16 ナイセリア・メニンギティディスのワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020150938A Active JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン
JP2022021720A Active JP7329087B2 (ja) 2016-09-02 2022-02-16 ナイセリア・メニンギティディスのワクチン

Country Status (24)

Country Link
US (4) US11147866B2 (enExample)
EP (2) EP3506935B1 (enExample)
JP (3) JP6764021B2 (enExample)
KR (1) KR102692762B1 (enExample)
CN (2) CN118236477B (enExample)
AU (2) AU2017321863B2 (enExample)
BR (1) BR112019003992A2 (enExample)
CA (1) CA3033364A1 (enExample)
DK (1) DK3506935T3 (enExample)
ES (1) ES2974992T3 (enExample)
FI (1) FI3506935T3 (enExample)
HR (1) HRP20240433T1 (enExample)
HU (1) HUE066007T2 (enExample)
LT (1) LT3506935T (enExample)
MX (1) MX2019002489A (enExample)
PH (1) PH12019500399B1 (enExample)
PL (1) PL3506935T3 (enExample)
PT (1) PT3506935T (enExample)
RS (1) RS65362B1 (enExample)
SA (1) SA519401227B1 (enExample)
SG (1) SG11201901394XA (enExample)
SI (1) SI3506935T1 (enExample)
WO (1) WO2018045286A1 (enExample)
ZA (1) ZA201901402B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543907A (ja) * 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
PT3506935T (pt) 2016-09-02 2024-04-01 Sanofi Pasteur Inc Vacina contra neisseria meningitidis
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
JP2024507828A (ja) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド B群髄膜炎菌組換えワクチン
JP2025512330A (ja) 2022-04-11 2025-04-17 サノフィ パスツール インコーポレイテッド シアノ水素化ホウ素ナトリウムとのタンパク質-糖コンジュゲーション
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
PL175595B1 (pl) * 1992-08-31 1999-01-29 North American Vaccine Inc Antygenowy/immunogenny koniugat do wytwarzania szczepionki przeciwko infekcji N.meningitidis, sposób wytwarzania antygenowego/immunogennego koniugatu oraz szczepionka przeciwko infekcji N.meningitidis
DE69628418T2 (de) 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖-蛋白质缀合物或寡糖-蛋白质缀合物、其制备方法及其应用
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
EP2279748A1 (en) 2000-06-29 2011-02-02 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition
US6673905B2 (en) 2000-08-09 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Conjugation of biomolecules using Diels-Alder cycloaddition
JP2005504718A (ja) * 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
DK1490409T3 (da) 2002-03-26 2009-03-23 Novartis Vaccines & Diagnostic Modificerede saccharider med forbedret stabilitet i vand
WO2003094961A1 (en) 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
AU2003299501A1 (en) 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
EP1624888B1 (en) 2003-05-07 2016-10-12 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccine
US6933137B2 (en) 2003-05-16 2005-08-23 Aventis Pasteur Animal component free meningococcal polysaccharide fermentation and seedbank development
CA2530364C (en) 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
ES2317043T3 (es) 2003-06-23 2009-04-16 Baxter International Inc. Proteinas portadoras para vacunas.
AU2004263135B2 (en) 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23236A1 (es) 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1776389B1 (en) 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
AU2005279821A1 (en) 2004-08-30 2006-03-09 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
CA2580693A1 (en) 2004-09-21 2006-03-30 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2006042542A2 (en) 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
PT1885734E (pt) 2005-05-06 2015-03-04 Novartis Ag Imunogénios para vacinas contra a meningite-a
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
JP2008543907A (ja) 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB0513071D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
CA2621578C (en) 2005-09-05 2014-07-22 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
EA014107B1 (ru) 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
MX2007007790A (es) 2005-12-22 2009-06-05 Sanofi Pasteur Inc Conjugados y vacuna de proteina con polisacarido derivado meningococcal multivalente.
EP1976857A4 (en) 2006-01-13 2011-08-03 Baxter Int PROCESS FOR CLEANING POLYSACCHARIDES
EP3006041B1 (en) 2006-03-17 2017-11-29 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
CU23575A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
CU23572A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2654706A1 (en) 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
JP5745221B2 (ja) 2006-08-07 2015-07-08 プレジデント アンド フェローズ オブ ハーバード カレッジ タンパク質マトリックスワクチンおよびそのようなワクチンの製造方法および投与方法
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2155244B1 (en) 2007-04-23 2017-03-22 Serum Institute of India Private Limited Antigenic polysaccharides and process for their preparation
JP5637848B2 (ja) 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
WO2008157590A1 (en) 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
EP2173759A4 (en) 2007-07-03 2014-01-29 Childrens Hosp & Res Ct Oak OLIGOSIAL INSERTS, PROCESS FOR THEIR PREPARATION AND ITS IMMUNOLOGICAL USE
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
GB0810894D0 (en) 2008-06-13 2008-07-23 Novartis Vaccines & Diagnostic Conjugated saccharide
MX351810B (es) 2008-07-21 2017-10-27 Brigham & Womens Hospital Inc Metodos y composiciones que se relacionan con oligosacaridos sinteticos de beta-1, 6 glucosamina.
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US9358302B2 (en) 2009-03-23 2016-06-07 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー E.coliキャリアタンパク質に結合体化した多糖免疫原
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AU2011268507B2 (en) * 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
CA2752980C (en) 2010-09-23 2018-06-19 Anhydrovac Inc. Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012158701A1 (en) 2011-05-18 2012-11-22 Matrivax Research & Development Corporation Protein matrix vaccine compositions including polycations
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー spr0096抗原およびspr2021抗原を含むキャリア分子
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
IN2012MU00206A (enExample) * 2012-01-20 2013-08-09
US9198977B2 (en) 2012-01-30 2015-12-01 Serum Institute Of India Ltd. Immunogenic composition
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
CN104428008B (zh) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) 多价脑膜炎球菌缀合物及制备缀合物的方法
CN104602696A (zh) 2012-05-30 2015-05-06 布赖汉姆妇女医院 多糖组合物及使用方法
WO2014009971A2 (en) 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
HUE049531T2 (hu) 2012-08-16 2020-10-28 Pfizer Glikokonjugációs eljárások és kompozíciók
CN102809656B (zh) 2012-08-26 2014-09-03 云南沃森生物技术股份有限公司 一种脑膜炎球菌多糖结合疫苗成品各群游离多糖含量的测定方法
BR112015005056A2 (pt) * 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
EP2903650B1 (en) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Nonlinear saccharide conjugates
WO2014080423A2 (en) 2012-11-21 2014-05-30 Serum Institute Of India Ltd. Production of high yields of bacterial polysaccharides
SI3363806T1 (sl) 2012-12-20 2023-04-28 Pfizer Inc. Postopek glikokonjugacije
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
PT2976101T (pt) 2013-03-18 2020-11-12 Glaxosmithkline Biologicals Sa Método de tratamento
EP2999709A4 (en) 2013-05-20 2016-12-07 Shantha Biotechnics Private Ltd PURIFICATION OF PROTEIN-POLYSACCHARIDE CONJUGATES
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
MX2016000393A (es) 2013-07-11 2016-10-26 Novartis Ag Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
WO2015052684A2 (en) 2013-10-11 2015-04-16 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
WO2015084846A1 (en) 2013-12-02 2015-06-11 Brandeis University High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
MY186874A (en) 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
JP6526692B2 (ja) 2014-02-25 2019-06-05 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. 髄膜炎菌(Neisseria meningitidis)血清型Xの新規の合成オリゴマー及びその調製方法
WO2015158898A2 (en) 2014-04-17 2015-10-22 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
EP3148577B1 (en) 2014-05-24 2021-01-20 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
US10105438B2 (en) * 2014-10-09 2018-10-23 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Process of conjugation and novel synthetic oligosaccharide-protein conjugates obtained thereof
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
EP3288983B1 (en) 2015-04-28 2025-10-29 Biological E Limited Method for separation of protein and other impurities from microbial capsular polysaccharides
CN104998255B (zh) 2015-06-30 2018-08-28 北京祥瑞生物制品有限公司 新型acyw135群脑膜炎球菌结合疫苗及其制备方法
AU2016290233A1 (en) 2015-07-04 2018-01-25 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
CN105061629A (zh) 2015-08-31 2015-11-18 成都欧林生物科技股份有限公司 A群脑膜炎球菌荚膜粗多糖纯化工艺
CN108473945A (zh) 2015-11-17 2018-08-31 辉瑞公司 用于在细菌细胞培养物中生产多糖的培养基和发酵方法
BR112018068523A2 (pt) 2016-03-15 2019-01-22 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd novos conjugados de polissacarídeo-proteína e processo para obter os mesmos
PT3506935T (pt) 2016-09-02 2024-04-01 Sanofi Pasteur Inc Vacina contra neisseria meningitidis
EP3585427A4 (en) 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS

Similar Documents

Publication Publication Date Title
JP2019526573A5 (enExample)
JP4653131B2 (ja) 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
JP5346308B2 (ja) ワクチン組成物
JP5814507B2 (ja) ワクチン
JP6884145B2 (ja) 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
JP5401012B2 (ja) B型インフルエンザ菌糖ワクチン用ポリアニオン性ポリマーアジュバント
JP2005508849A5 (enExample)
US20100074918A1 (en) Vaccine
JP2014506916A5 (enExample)
JP2009525260A5 (enExample)
JP2021001182A5 (enExample)
KR20080079697A (ko) 컨쥬게이트 백신
US20090214586A1 (en) Combination Vaccines With Whole Cell Pertussis Antigen
Xu et al. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein
US20150125486A1 (en) Adjuvanted formulations of pediatric antigens
JP2019142898A (ja) 治療方法
AU2013203161A1 (en) Vaccine